Eli Lilly Inks $1.9B RNA-Editing Alliance, Signals M&A Push

Daily Biopharma Digest — June 3, 2026

• Eli Lilly extended its dealmaking streak with a $1.9 billion RNA-editing partnership with Ascidian for kidney disease therapies.
• Lilly signals more acquisitions into new therapeutic areas fueled by GLP-1 revenues.
• ASCO 2026 wrapped with Revolution Medicines, Merck, and Lilly headlining the conference’s biggest clinical winners.
• A House bill targeting China biotech partnerships could reshape how U.S. pharma companies structure international deals.
• The FDA released draft guidance leveraging prior knowledge to expedite cell and gene therapy development.

What to Watch

• China Biotech Legislation — If the House bill advances, expect pharma companies to restructure China partnerships and potentially accelerate nearshoring of manufacturing and research operations, creating winners among domestic CROs and CDMOs.
• Lilly’s Diversification Strategy — With the company’s BD chief explicitly signaling more deals outside core franchises, watch for acquisitions in immunology, neuroscience, or rare disease that leverage Lilly’s GLP-1 cash flow to build defensible positions.
• RNA Editing Maturation — The Ascidian-Lilly partnership validates RNA exon editing as an investable platform; expect increased M&A activity and venture funding for RNA-editing companies as proof-of-concept data emerges.
• Male Contraceptive Market Development — Contraline’s Phase III progression will test whether payers and healthcare systems are prepared to support male-focused reproductive health products, potentially opening a new commercial category if successful.